Risk factors for cardiovascular events in patients treated with immunotherapy
| Autor: | Yago Garitaonaindia, Mariola Blanco, Fernando Franco, Maria Torrente, Virginia Calvo, Ana Collazo, Aranzazu Gonzalez del Alba, Juan Cristobal Sanchez, Lourdes Gutiérrez, Ana Royuela, Beatriz Nuñez Garcia, Miriam Mendez, Roberto Hernández, Blanca Cantos Sanchez de Ibarguen, Marta Martinez Cutillas, Cristina Traseira, Ramon Aguado, Guillermo Visedo Ceballos, Mariano Provencio |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 40:e18736-e18736 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2022.40.16_suppl.e18736 |
| Popis: | e18736 Background: Immunotherapy (IO) is increasingly widespread in current clinical practice; however, little is known about its cardiovascular safety profile. The aim of this study is to identify clinical factors that are associated with increased risk of having a cardiac event (CE). Methods: we conducted a retrospective study in a single institution including patients treated with IO from 2014 to 2020. We analyzed their clinical characteristics and the CE developed during IO treatment and compared those who had a registered CE with those who had not. Results: 378 patients were analyzed. After a mean-follow up 15.9 months, we registered the following CE: ECG abnormalities 12.2%, congestive heart failure 3.4%, pulmonary embolism 1.9%, coronary syndrome 0.8%, myocarditis 0.5% and pericarditis 0.5%. The specific cardiac mortality was 0.8%. Results are shown in Table. Conclusions: In our study, elder age, history of ischemic heart disease or arrythmia, and reporting other immune-related adverse events (irAE), appear to be risk factors for developing a CE during IO treatment. Although most are well-known cardiovascular risk factors, the relationship between other irAEs and CE should be highlighted, and prospective studies are needed to delve into this hypothesis.[Table: see text] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|